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Abstract: 
 
Background: Current guidelines recommend primary (PP), as opposed to secondary (SP) 
prophylaxis with granulocyte-colony stimulating factors (G-CSF), for adjuvant breast cancer  
chemotherapy (AC) regimens associated with a febrile neutropenia (FN) risk of ≥ 20%. The 
adoption of PP G-CSF for FN prevention in various health care jurisdictions may be affected by its 
value for money (i.e. cost-effectiveness). Design: A systematic review of all cost-effectiveness / 
cost-utility analyses (CEA / CUA) involving PP vs. SP G-CSF for breast cancer AC    was conducted 
to examine; i) cost-effectiveness of PP vs. SP; ii) FN threshold at which PP is cost-effective, and 
iii) potential impact of G-CSF efficacy assumptions on outcomes. Results: Of 114 publications 
identified, 5 CEA / CUA (USA = 1, UK = 1, Canada = 3) met the predefined inclusion / exclusion 
criteria. These CEA / CUA examined different AC regimens (TAC = 2; FEC-D = 1; TC = 2) and G-CSF 
formulations (filgrastim “F”= 4; pegfilgrastim “P” = 4) with varying baseline FN―risk (range 22 - 
32%), ―mortality (range 1.4 - 6.0%) and ―utility (range 0.33 - 0.47) assumptions. Potential G-
CSF benefit, including FN risk reduction with P vs. F, varied among models. Overall, relative to SP, 
PP G-CSF was not associated with good value for money, as per commonly-utilized CE thresholds 
at the baseline FN rates examined in most of these studies (n=4) including the consensus 20% FN 
threshold guideline. The value for money associated with PP vs. SP was primarily dependent on 
G-CSF benefit assumptions including reduced FN- mortality and improved BC survival. 
Conclusions: PP G-CSF for FN prevention in BC patients undergoing AC may not be a cost-effective 
strategy at the 20% baseline  FN risk threshold as recommended by current practice guidelines.   
 
 
Key Words: Febrile Neutropenia. G-CSF prophylaxis. Value for Money. Cost-Effectiveness. Breast 
Cancer. 
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INTRODUCTION 
Febrile neutropenia (FN) is associated with significant morbidity, mortality risk, and cost.(1,2,3,4)  It 
can also lead to adjuvant chemotherapy treatment delays and/or dose reductions that can 
potentially affect patient survival.(1,2) Patients developing FN are often prescribed granulocyte-
colony stimulating factors (G-CSF) with subsequent treatment cycles in an attempt to reduce the 
risk of further FN events (secondary prophylaxis; SP) and maintain chemotherapy relative dose 
intensity (RDI).(5,6,7) Current practice guidelines recommend G-CSF from the first cycle of 
chemotherapy (primary prophylaxis; PP) if the predicted FN risk is 20% or higher.(5,6,7) 
 
Globally, adjuvant chemotherapy for breast cancer often consists of taxane-based regimes such 
as TAC (Docetaxel, Doxorubicin, Cyclophosphamide), FEC-D (Fluorouracil, Epirubicin, 
Cyclophosphamide, Docetaxel) and TC (Docetaxel, Cyclophosphamide).(8,9,10) PP, as opposed to 
SP, is currently recommended for most patients treated with these regimens given the ≥ 20% FN 
risk observed with these regimens outside of clinical trials.(11) PP G-CSF could lead to lower FN-
management costs and improved patient quality of life due to a reduction in FN event rate, and 
may also be associated with lower FN-related mortality rates and/or improved long-term cancer 
survival due to improved chemotherapy delivery.(12,13,14,15,16) PP G-CSF is also associated with 
significant drug acquisition costs that should be examined within the context of all potential 
downstream cost savings, quality of life improvements and survival benefits.(17)  
 
The adoption of PP G-CSF for FN prevention in various health care jurisdictions could be affected 
by its value for money (i.e. cost-effectiveness).(18,19,20) Cost-effectiveness / cost-utility analyses 
(CEA / CUA) examine the incremental costs per life-year (LY) or quality-adjusted life-year (QALY) 
gained with an intervention, and can help address the question of “value in cancer care”.(21) 
Interventions associated with incremental costs per QALY gained below commonly utilized cost-
effectiveness (CE) thresholds (US$100,000[1] in the USA, £30,000 in the UK, and CAN$100,000 in 
Canada per QALY gained) are deemed to provide “good value for money”.(20, 22)  We conducted a 
systematic review to examine the “value for money” associated with PP vs. SP G-CSF for adjuvant 
chemotherapy in breast cancer. 
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METHODS 
Literature search strategy 
A literature search involving Pubmed and the Cochrane Database of Systematic Reviews was 
conducted on December 1, 2015 to identify all published CEA / CUA that examined G-CSF 
prophylaxis for FN risk reduction during adjuvant chemotherapy in breast cancer. The search 
included the following keywords: (economic, pharmacoeconomic, price, pricing, cost(s), cost 
analysis, or cost effective) AND (breast neoplasm(s) or breast cancer) AND (granulocyte colony-
stimulating factor, G-CSF, filgrastim, or pegfilgrastim). In addition, references from all studies 
identified by search above were hand searched to identify potentially overlooked studies 
(backward search).  
 
Inclusion and exclusion criteria 
Economic evaluations of G-CSF prophylaxis (filgrastim or pegfilgrastim) for FN prevention that 
met all the following eligibility criteria were included; i) CEA / CUA studies, ii) adjuvant 
chemotherapy for breast cancer, iii) PP vs. SP G-CSF strategies, IV) outcomes reported in 
incremental costs per LY or QALY gained. Studies were excluded as follows; i) review articles and 
commentaries, ii) economic evaluations other than CEA / CUA, iii) publications in a language 
other than English, iv) mixed populations involving various cancers if outcomes not reported 
separately for breast cancer, v) G-CSF strategies involved different backbone chemotherapy 
regimens, vi) G-CSF prophylaxis was intended for bone marrow or peripheral-blood stem-cell 
transplantation, and vii) baseline FN rate examined was not stated / defined.   
 
Data extraction & study aims  
The selected studies were reviewed to extract and/or compute all relevant data pertinent to 
study methods, including key input parameters of G-CSF benefit (i.e. improved quality of life, 
lower FN-related costs, reduced FN mortality, and improved breast cancer survival), and cost-
utility outcomes. All relevant data were extracted and/or computed by two authors (T.Y. and S.J.) 
with discrepancies resolved by consensus. The aims of this study were; i) to examine the value 
for money (i.e. cost-effectiveness) of PP vs. SP G-CSF for adjuvant chemotherapy in breast cancer, 
ii) to identify the FN rate at which PP G-CSF appearsto be a cost-effective strategy, and its value 
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for money at the consensus guideline 20% FN threshold, and iii) to evaluate the potential impact 
of G-CSF efficacy assumptions on outcomes.  
 
RESULTS 
Identified studies 
The initial search returned 114 publications (Figure 1). Eighty were excluded based on the title 
and a further 29 after a more detailed review of the abstract / publication. Five studies met the 
predefined inclusion / exclusion criteria, and were included in this review (Table 1).(23,24,25,26,27) 
Backward search did not identify any other eligible studies. The included studies were conducted 
in different health care jurisdictions (USA = 1, UK = 1, Canada = 3), involved commonly utilized 
adjuvant taxane-based regimens (TAC = 2; FEC-D = 1; TC = 2), and all reported on incremental 
costs per QALY gained, albeit at different time horizons (range: 3-month to lifetime). 
 
Study methods 
All studies assumed a baseline FN risk greater than 20% (range 22 ― 32%), and varying impacts 
of FN on quality of life and/or mortality (Table 1). All evaluations incorporated PP G-CSF for all 
chemotherapy cycles, with one (25) also examining PP G-CSF for the D cycles only (FN risk 14.8%) 
of FEC-D. All studies incorporated lower FN-related costs and improved patient quality of life due 
to reductions in FN event rate following G-CSF prophylaxis, but incorporated varying survival 
benefits due to lower short-term FN-related mortality and/or improved long-term breast cancer 
survival (Table 2). A public payer perspective was considered by all evaluations, and none 
accounted for indirect costs or took a societal perspective. Overall, upfront costs of G-CSF drug 
acquisition and downstream costs of FN management were highest in the USA and lowest in the 
UK (Table 3).   
 
Value for money of PP vs. SP G-CSF strategies  
PP G-CSF with filgrastim (Table 4) or pegfilgrastim (Table 5), was associated with both incremental 
cost and QALY gains relative to SP in all studies at the baseline FN rate examined in each. Overall, 
the computed incremental cost per QALY gained was higher than commonly utilized CE 
thresholds except in the evaluation (25) that examined PP G-CSF only for the D cycles of FEC-D 
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chemotherapy. In all other evaluations,(23,24,26,27) PP G-CSF was associated with a less than 50% 
(range 5 - 42%) probability of being a cost-effective strategy when judged against commonly 
utilized CE thresholds in the various jurisdictions studied. In sensitivity analyses, the value for 
money of PP G-CSF was primarily dependant on  FN mortality rate assumptions,(23,25,26) baseline 
FN rate,(23,24,25,26) G-CSF costs,(23,24,25,26) and impact of PP on FN rate(23,26). Conversely, FN utility 
(23,26) and chemotherapy characteristics,(26) including price and relative effectiveness, appeared 
to have relatively little impact on G-CSF value for money. Finally, FN management costs (23,25,26) 
had less significant [DR2]impact on G-CSF cost-effectiveness.     
                             
Impact of baseline FN rate and the consensus guideline 20% threshold  
Unsurprisingly in all evaluations, higher FN rates were associated with improved cost-
effectiveness. Except for the one study utilizing PP G-CSF for the D cycles of FEC-D chemotherapy 
only,(25) no study examining PP G-CSF at a baseline 20% FN rate found it to be associated with 
acceptable value for money although all found it to be a cost-effective strategy at higher FN rates. 
In one Canadian study,(26) PP G-CSF with filgrastim would meet a $100,000/QALY gained 
threshold at a FN rate > 28% assuming some loss of chemotherapy efficacy at lower 
chemotherapy doses, and at a > 22% rate assuming further loss of chemotherapy efficacy with 
every FN event regardless of subsequent chemotherapy doses. In the UK study,(24) PP G-CSF with 
pegfilgrastim would meet a £30,000/QALY gained threshold at a FN rate greater than 29%. 
Finally, in the US study,(23) a FN rate of 40% but not 20% was associated with CE less than the 
$100,000/QALY gained threshold ($49,000 vs. 156,000 / QALY gained, respectively).  
 
Impact of G-CSF benefit assumptions 
The cost-effectiveness of PP G-CSF appears to be primarily dependent on assumed survival 
benefits (i.e. reduced FN deaths and improved breast cancer survival). Indeed, in the one study 
that assumed no survival benefit,(27) PP vs. SP was associated with a very small 0.001 QALY gain 
and highly unfavourable cost-effectiveness estimates (ICER 2,348,924 per QALY gained) despite 
a significant 31% lower absolute FN event rate (1% vs. 32%, respectively). In the US and UK 
evaluations,(23,24) sensitivity analyses that  tested the impact of PP G-CSF benefit on breast cancer 
survivalfound a positive relationship between survival benefit and value for money. Most 
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importantly perhaps, the impact of the assumed reduction in short-term FN deaths was more 
pronounced than the impact of any assumed improvements in long-term breast cancer survival. 
In one Canadian study for example,(26) the benefits [DR3]of PP G-CSF were primarily driven by FN-
related mortality avoided (3.5 deaths [DR4]per 1000 treated) and not the breast cancer relapses 
prevented due to improved chemotherapy delivery. As well, the more favourable CE results 
reported in another Canadian study (25) likely partly reflect a higher  assumed FN mortality risk 
(6%: range 4.5-7.6%) compared with other studies (range 1.4 ― 3.6%), resulting in significantly 
larger numbers of FN-deaths avoided (7.3 - 10.8 and 8.7 - 12.5 per 1000 treated with filgrastim 
and pegfilgrastim, respectively) with no assumed improvement in breast cancer survival.  
 
DISCUSSION 
The adoption of various medical interventions depends partly on clinical benefit / risk profile and 
“value for money” among other factors(18,19) The assumed thresholds at which an intervention is 
assumed to be providing good value for money varies between nations as well as health authority 
jurisdictions and can also vary over time. The value for money of PP G-CSF in the identified studies 
was judged against commonly employed CE thresholds in the relevant jurisdictions (US$100,000 
in the USA, £30,000 in the UK, and CAN$100,000 in Canada per QALY gained) but society and 
payers may adopt higher thresholds.(18,19,20) For example, the World Health Organization (WHO) 
defines the “value for money” of interventions relative to gross domestic product (GDP) per 
capita and defines these as being; i) highly cost effective (< GDP /capita), ii) cost-effective (1–3 
times GDP / capita) and iii) not cost effective (>3 times GDP / capita).(22) Value for money should 
therefore be considered within the context of acceptable and perhaps evolving “willingness to 
pay” (WTP) thresholds. 
 
The value for money of medical interventions depends on upfront cost and downstream benefit 
and includes cost savings due to the intervention as well as improvements in quality of life and 
survival. The identified CUAs, from the US, UK and Canada, with varying modeling assumptions 
and input parameters provide a unique opportunity to examine key drivers of the value for 
money associated with PP G-CSF across various health care jurisdictions.(23,24,25,26,27) Overall, and 
not surprisingly, the CE of PP G-CSF was affected by baseline FN risk and acquisition cost. The 
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adoption of PP G-CSF for higher FN risk scenarios as well as successful price negotiations aimed 
at lowering acquisition cost would improve the value for money further. Perhaps most 
importantly, despite the observed heterogeneity in study parameters and  assumptions across 
the identified CUAs, the value for money of PP G-CSF appears primarily dependent on 
assumptions regarding potential short-term survival benefits achieved with PP G-CSF as opposed 
to improved quality of life or reduced costs. If the benefits of PP G-CSF were limited to improved 
FN costs and quality of life, PP G-CSF does not appear to be associated with good value for money.   
 
Our systematic review and derived conclusions, have limitations. Firstly, and perhaps most 
importantly, the CUAs identified have incorporated different key assumptions regarding G-CSF 
benefits on short-term FN-related mortality and long-term cancer survival among other 
parameters. Indeed, the potential long-term survival benefit associated with PP G-CSF is not well 
defined to date, in particular with regard to long-term breast cancer specific survival due to 
improved chemotherapy delivery.(14,15,16) Clinical practice guidelines should attempt to provide 
clear consensus statements regarding the survival benefits achieved with PP G-CSF, if any. 
However, this heterogeneity in methods, assumptions and values can also be seen as a strength 
as it confirms the robustness of the overall findings of this review. Indirect costs such as lost 
productivity and caregiver costs were not considered in any of the CEA / CUAs identified. Value 
for money would be more favorable if these societal / indirect costs were also incorporated. A 
direct payer as opposed to a societal perspective, however, is routinely employed by drug funding 
regulatory agencies, such as the National Institute for Health and Care Excellence (NICE) and the 
pan-Canadian Oncology Drug Review (pCODR) - Expert Review Committee (pERC) in the UK and 
Canada, respectively, when addressing the value of cancer care.(28,29)       
 
PP G-CSF in breast cancer appears to be associated with incremental costs per QALY gained that 
are higher than commonly utilized CE thresholds at the baseline FN risks and G-CSF assumptions 
examined in almost all evaluations incorporating adjuvant TAC, FEC-D and TC chemotherapy 
regimens. More importantly, PP G-CSF did not appear to provide good value for money at the 
20% FN threshold currently recommended by practice guidelines (5,6,7) despite assuming a FN 
mortality benefit. PP G-CSF would be associated with better value for money at higher baseline 
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FN risk and/or higher WTP thresholds, and would also likely be cost-effective if it was also 
associated with significant improvements in long-term cancer survival due to improved 
chemotherapy delivery. Further clinical research is required to further elucidate the potential 
impact of PP G-CSF on acute FN-related mortality and long–term effects on cancer survival to 
more precisely determine the overall net cost-effectiveness of the intervention.      
 
KEY MESSAGE  
Current guidelines recommend primary prophylaxis with granulocyte-colony stimulating factors 
(G-CSF) for adjuvant chemotherapy regimens associated with a febrile neutropenia risk ≥ 20%. 
Primary prophylaxis with G-CSF for febrile neutropenia prevention in adjuvant chemotherapy 
for breast cancer may not be a cost-effective strategy at the current consensus guideline 20% 
FN threshold.  
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Table 2: G-CSF Parameters 
Table 3: Costing Parameters  
Table 4: Cost-Utility of Filgrastim Primary vs. Secondary G-CSF Prophylaxis               
Table 5: Cost-Utility of Pegfilgrastim Primary vs. Secondary G-CSF Prophylaxis  
 
 
FIGURES 
Figure 1: CONSORT diagram   
This figure shows a flow diagram of the search strategy and reasons for publication exclusion. 
PP, primary prophylaxis; SP, secondary prophylaxis; G-CSF, granulocyte colony-stimulating factor; 
∆, incremental. 
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